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AbstrACt
Numerical data in biology and medicine are commonly 
presented as mean or median with error or conidence 
limits, to the exclusion of individual values. Analysis of 
our own and others’ data indicates that this practice 
risks excluding ‘Goldilocks’ effects in which a biological 
variable falls within a range between ‘too much’ and ‘too 
little’ with a region between where its function is ‘just 
right’; a concept captured by the Swedish term ‘Lagom’. 
This was conirmed by a narrative search of the literature 
using the PubMed database, which revealed numerous 
relationships of biological and clinical phenomena of 
the Goldilocks/Lagom form including quantitative and 
qualitative examples from the health and social sciences. 
Some possible mechanisms underlying these phenomena 
are considered. We conclude that retrospective analysis of 
existing data will most likely reveal a vast number of such 
distributions to the beneit of medical understanding and 
clinical care and that a transparent approach of presenting 
each value within a dataset individually should be adopted 
to ensure a more complete evaluation of research studies 
in future.
IntroduCtIon
Numerical data in science and medicine 
have traditionally been presented as mean 
or median values with SEs or SDs. Such data 
commonly take the form of tables, bar graphs 
or line graphs. However, as Weissgerber et 
al1 point out, this practice poses a problem 
since different distributions of data can lead 
to the same bar or line graph. This was well 
illustrated elegantly by George et al2 who 
used illustrative data from a hypothetical 
experiment to examine the impact of three 
different cell lines on drug receptor activation 
and showed that a variety of distributions of 
individual data points can lead to similar bar 
graphs with the same mean (figure 1). This is 
because bar charts frequently do not convey 
major features of the dataset adequately. As 
figure 1 makes clear, moving away from using 
bar charts to visualise the entire dataset is a 
necessary refinement that can increase the 
transparency and reporting of data.
The attention paid to individual variation 
in cellular and molecular biological and 
clinical studies is relatively recent, but has 
been well- known for many years to ecolo-
gists, especially following the publication by 
Albert F Bennett,3 in 1987, of an influential 
article entitled: ‘Inter- individual variability: an 
underutilized resource’. Bennett, an ecological 
physiologist, pointed out that mean values 
with CIs about the mean, once published 
tend to ‘—take on a life of their own, and become 
the only point of analysis and comparison’ to the 
exclusion of the individual values, and their 
potential significance. Bennett referred to 
this tendency as ‘the tyranny of the Golden Mean’, 
and as an alternative, advocated the analysis 
of interindividual variability, that is, the full 
range of individual values, he considered 
could provide the observer with a greater 
interpretative repertoire.
In the time since Bennett’s paper, there has 
been a movement away from the tyranny of 
the mean in many areas of biology, notably in 
ecology.4 Examples are provided by Stephen 
J Gould,5 who wrote an article on ‘The median 
isn’t the message’, Hayes and Jenkins6 on indi-
vidual variation in mammals, and Lloyd- 
Smith7 on the spread of epidemics of human 
disease.
Our interest in interindividual variability 
arose particularly from research in which we 
have been involved on (1) the development 
and metabolism of single preimplantation 
mammalian embryos (DRB, HJL, RS) and 
(2) of glycaemic control in individual human 
subjects (TS).
development and metabolism of single 
preimplantation embryos
Data which illustrate the value of distribu-
tions rather than mean or median values 
were provided by Guerif et al8 who measured 
the consumption of the essential nutrient, 
pyruvate, by single bovine preimplantation 
embryos at the zygote stage (1 cell fertilised 
egg; day 1 of development). The experiments 
revealed considerable heterogeneity between 
individual embryos such that it was possible 
to divide them prospectively into three 
groups—of ‘high’, ‘intermediate’ and ‘low’ 
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Figure 1 An illustrative example of a comparison of cell 
lines is described, which shows that bar charts do not 
give the reader adequate information on the variability and 
distribution of each sampled ‘n’. The extent of activation 
of a receptor in three cell lines a, b and c under baseline 
(drug‐naïve) conditions and following the addition of a drug is 
given in arbitrary units. The same datasets are presented in 
three different ways: (A) bar chart, (B) grouped column scatter 
plot with means and error and (C) before–after scatter plot. 
n=10 (ie, biological replicates and not technical replicates). 
In this example, error bars represent the SEM although 
authors should consider the sampling size and distribution 
of ‘n’ when choosing the most appropriate way of showing 
experimental error (eg, SD or CI).
pyruvate consumption at an early stage (day 2)—and 
track their subsequent development to the blastocyst 
stage, a critical developmental endpoint. These data indi-
cated that intermediate values of pyruvate consumption 
correlated with viability (capacity to form a blastocyst), 
though with considerable overlap between the catego-
ries. Put another way, which takes account of this overlap, 
plotting individual values revealed the existence of an 
optimal ‘range’ of metabolic activity. This concept was 
developed in a follow- up paper9 in which we proposed 
that the optimal range was equivalent to a ‘Goldilocks 
zone’ or as it is known in Sweden, of ‘Lagom’, meaning 
‘just the right amount’, in which embryos with maximum 
developmental potential are located.
Glycaemic control
Glycated haemoglobin (HbA
1c
) is a marker of glycaemic 
control in patients with diabetes which is commonly used 
in clinical practice. Indeed, HbA
1c
 is the recommended test 
for diagnosing diabetes.10 There is an association between 
the extent of high blood glucose as measured by HbA
1c
 
and the risk of death and of macrovascular and microvas-
cular disease in patients with type 2 diabetes (T2DM).11 
In the landmark UK Prospective Diabetes Study, intensive 
glycaemic control that aimed to achieve a HbA
1c
 level of 7% 
or below was associated with improved outcome in newly 
diagnosed patients with T2DM.12 This finding was then 
extrapolated to all patients with T2DM, and as a result, 
lower HbA
1c
 levels were recommended for management of 
patients with T2DM. However, concerns arose as data from 
the Action to Control Cardiovascular Risk in Diabetes trial 
began to emerge showing increased all- cause mortality and 
cardiovascular mortality in the intensive treatment group 
who were treated with antihyperglycaemic agents aiming 
for a lower HbA
1c
 target of 6% compared with conventional 
antihyperglycaemic treatment in patients with T2DM 
aiming for HbA
1c
 of 7%–7.9%. These results led to early 
termination of the trial.13 Further studies14 15 have demon-
strated that lower and higher mean HbA
1c
 values were asso-
ciated with an increased risk of cardiovascular events and 
mortality suggesting a ‘Goldilocks’ or Lagom state of HbA
1c
 
is the optimal.
Similar ‘U’ shaped associations with HbA
1c
 and 
all- cause mortality have also been shown for type 1 
diabetes.16 Even in patients without diabetes, extremes 
of glycaemia as measured by HbA
1c
 are associated with 
adverse clinical outcomes including cardiovascular 
events and all- cause mortality. Similar increases in 
mortality in either extremes are seen with body weight, 
blood pressure, birth weight, cholesterol and other 
cardiovascular risk factors.
GoldIloCks And lAGom
The Goldilocks zone has been defined mathematically by 
Kohn and Melnick17 in the context of xenobiotic ligand 
binding to nuclear receptors as a ‘Non- monotonic receptor- 
mediated dose- response curve’ (NMDRC), and by Vanden-
berg18 in the context of endocrine disrupting chemicals as 
‘a response where the slope of the curve changes sign from positive to 
negative or vice versa somewhere along the range of doses examined’. 
These are valuable definitions because they can be applied 
to all non- linear distributions including U- shaped, inverted 
U- shaped, J- shaped, sigmoidal and reverse sigmoidal.
The U- shaped curve is probably the most widely 
observed. It usually refers to the nonlinear relation-
ship between two variables, in particular, a dependent 
and an independent variable. Because many analytical 
methods assume an underlying linear relationship, 
systematic deviation from linearity can lead to bias in 
estimation of safe levels in exposure to nutrients, drugs 
or toxic agents (for a discussion, see section Mecha-
nisms underlying the Goldilocks principle and what is 
Lagom and Vandenberg18).
How wIdespreAd Is tHe presenCe of A GoldIloCks zone 
In bIoloGy And medICIne?
We thought it might be instructive to discover how widely 
the notion of a Goldilocks zone is a feature of the wider 
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biological literature, especially as applied to medicine. 
A comprehensive search for information conducted 
on the PubMed database in early 2018 using the term 
‘Goldilocks’ revealed 184 entries, all of which have been 
examined, together with the grey literature. Only articles 
in English language were selected. A selection of 43 of 
these publications has been presented (online supple-
mentary appendix 1) as representative of the range of 
phenomena which invoke the Goldilocks concept in 
order to increase biological and clinical understanding. 
It should be emphasised that this is a narrative review 
rather than systematic review and no judgement on the 
quality of these studies or of those which have been 
omitted is implied.
Inspection of these examples reveals the wide range of 
biological and clinical phenomena in which Goldilocks 
zones have been found including the health and social 
sciences which can be qualitative rather than quantitative. 
It seems likely that a vast number remain to be discovered 
and that authors could, in a relatively simple manner, 
derive added value from their existing data by presenting 
distributions rather than median/mean values, and 
making raw data available to the research community via 
online repositories. This would allow systematic reanal-
ysis by data scientists with an interest in the Goldilocks/
Lagom concept.
meCHAnIsms underlyInG tHe GoldIloCks prInCIple And 
wHAt Is lAGom
mechanisms which are global in scope
We previously proposed an explanation that may account 
for Goldilocks/Lagom phenomena, derived from our 
work on energy efficiency in early mammalian embryo 
development9 which made use of an account of general 
aspects of biological optimisation by Johnson.19 The 
premise was that living things aim to function with the 
minimum input of energy, that is, with high energetic 
efficiency. To accomplish this will obviously require a 
threshold level of metabolic activity to ensure a given 
process proceeds in an optimum, yet efficient manner, 
while the upper limit will be set by the capacity to 
increase metabolism versus ‘the energy parsimony in almost 
everything (living things) do’.19 The Goldilocks/Lagom 
zone will obviously lie between these extremes. The 
boundaries will be set by homeostatic mechanisms at all 
levels of organisation. Such boundaries will be flexible 
in order to allow for the capacity to upregulate or down-
regulate metabolism in response to stress. Responses of 
these types have been usefully categorised by ecologists 
to distinguish (1) modest changes in metabolism (up or 
down within the optimum (Goldilocks/Lagom) range) 
from which the cell/organism can recover (the so- called 
Pejus range) and (2) extreme perturbation beyond the 
optimum which shifts metabolism irreversibly into a 
Pessimum range which is fatal (see figure 1 in the work of 
Sokolova).20
speciic mechanisms
Specific mechanisms for the production of NMDRCs were 
well summarised by Vandenberg18 in terms of the effect 
of endocrine disrupting chemicals, notably Bisphenol A 
on cells in culture, whole organisms, laboratory animals 
and human populations. Interestingly, it was reported 
that NMDRCs were common, comprising 20%–30% of 
all studies examined, depending on the conditions; for 
example, in vivo versus in vitro. Mechanisms considered 
included cytotoxicity,21 inhibition of cell proliferation22; 
hormone receptors produced versus degraded23; cell and 
tissue- specific cofactors24 and pharmacological effects. 
At the whole body level, examples of NMDRCs in nutri-
tion are widespread, reflecting minimum requirments 
at the lower end of the distribution and toxicity at the 
higher, for example, vitamin A. Vandenberg18 concludes 
that ‘strong evidence for Non- monotonic receptor- mediated dose- 
response curves’—question the current risk assessment practice 
where ‘safe’ levels are predicted from high dose exposures’
ConClusIon
There has long been a fixation in the biological and clin-
ical research communities with presenting data solely 
as measures of dispersion (means and medians) and 
of central tendency (eg, SD and IQR). We believe that 
the retrospective analysis of existing data could reveal 
numerous potential relationships with a Goldilocks/
Lagom pattern.
Interestingly, the editors of the British Journal of Phar-
macology 2 ‘will now require that, where possible, numerical 
data (whether categorical or continuous), particularly involving 
two sets or paired data, should be presented using scatter- plots, 
before- after graphs, and other forms in which each individual 
‘n’ value is individually plotted, rather than using bar charts. 
Authors presenting data as bar charts should state that a scatter 
plot or before–after charts did not reveal unusual or interesting 
aspects of the data not obvious from the bar chart’.
We believe the Journal should be complimented on this 
approach and urge all such journals to adopt it.
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